Pharmaceutical Technology’s Post

The blood–brain barrier has proven to be a significant obstacle for drug administration in the past. However, being able to traverse this barrier and treat diseases that affect the brain, such as Alzheimer's disease, is getting slightly easier thanks to innovative technology like Aliada Therapeutics' MODEL platform. To learn more about this exciting new tool and the potential impact it may have on therapeutic delivery for brain-related conditions, Joe Petroziello, EVP, Global Medical Affairs & Corporate Development, MJH Life Sciences®, chatted with John Dunlop, PHD, chief scientific officer, Aliada Therapeutics, at #BIO2024 https://lnkd.in/ehKRgPPm

It's always good to hear great news about revolutionary treatments, and that's just what Eisai US and Biogen have announced at the recent Alzheimer's Association International Conference in Philadelphia for their Alzheimer's drug, Leqembi. Three-year data showed that continued use of Leqembi significantly slows cognitive decline in early-stage Alzheimer's patients by 31%, with no new safety issues. This builds on the 27% reduction in cognitive decline observed after 18 months, which supported Leqembi's approval last year. Further improvement over use with no extra safety concerns is undoubtedly good news for sufferers of Alzheimer's and their families, alongside good news with Eli Lilly and Company recently receiving approval for a competitor drug in donanemab! Follow Warman O'Brien for more updates in the life sciences industry! #LifeSciences #AlzheimersResearch #Biotech #Eisai #Biogen #InnovationInHealth #Leqembi #HealthcareAdvancements

Join the global cannabis sciences community as we come together under one virtual roof for Labroots’ 7th Annual Cannabis Sciences Virtual Event on April 17th, 2024. You won’t want to miss a remarkable lineup of distinguished speakers who will delve into the latest research and developments within this dynamic field. This year’s theme is “Cannabis in 2024: The Science, Research, Legislation, and Medical Updates” and will explore the following tracks and topics: Trending Topics: - Psychedelics - Novel Cannabinoids and its Affects - Therapeutic Application of Terpenes Cannabis in Medicine: Therapeutic Applications and Case Studies - Cannabis in Integrative Medicine - Updates on Research Regulatory Updates in Cannabis - Scheduling Reform Updates Analytical Updates - Lab Shopping and Implementation of Standard Methods - ISO 17025 in Action: Setting Up a Compliant Cannabis Testing Lab - The Intersection of Cannabis Testing, Artificial Intelligence, and Safety Standards - Leveraging LIMS for Enhanced Productivity Understanding, Testing, and Combatting Hot Latent Viroid in the Cannabis Sector Get ready for a full day of insight and innovation as we dive headfirst into the fascinating world of cannabis sciences. Learn more and register here for free: https://buff.ly/48MERQ5 #LRcannabis

Our research efforts aim at delivering potential therapies to address unmet patient needs, and in doing so provide solutions that may benefit societies. One approach towards this ambition is with less frequent administration of treatments, and I am pleased to share that Novo Nordisk is expanding our engagement in this endeavour through an exciting new partnership with Ascendis Pharma.    We will build upon our expertise in cardiometabolic conditions in utilising Ascendis’s unique TransCon™ technologies to advance therapies that aim at less frequent dosing and thereby potentially better adherence. This means that our collaborative efforts could lead to better health outcomes and improved quality of life for individuals living with serious chronic disease.     For these reasons, I am looking forward to expanding our internal research efforts with this new technology partnership. Our work will initially focus on a GLP-1 receptor agonist. #EarlyResearch #Innovation #DrivingChange 

Benedict C. Albensi, Ph.D., chair, department of pharmaceutical sciences and professor recently gave with the Society of Clinical Research Associates on “Clinical Trials on Alzheimer’s Disease: Challenges and Opportunities.”   Clinical trials targeting Alzheimer's disease face multifaceted challenges amidst promising opportunities. Challenges include patient recruitment, high attrition rates, and complex trial designs. Additionally, the disease's heterogeneous nature poses diagnostic and treatment challenges. However, advancements in biomarkers, precision medicine, and collaborative research efforts offer opportunities for innovative trial designs and targeted therapies. Addressing these challenges while leveraging emerging opportunities is crucial for advancing Alzheimer's disease clinical research and developing effective treatments for this devastating condition.   Check out the recording on YouTube at: https://lnkd.in/ezzvnigX   #nsuflorida #nsusilvermancollegeofpharmacy #pharmacist #pharmacy #pharmacystudent #futurepharmacist #pharm4me #pharmacyschool #research #clinicalresearch #SOCRA #alzheimers

🌟 Advancing Drug Discovery in Liver Disease: The MASH CALL Initiative 🌟   🔍 Identifying the best candidates early on to minimize attrition rates is one of the biggest challenges in #drugdiscovery. To address this, there's an increasing need for advanced in vitro 3D models that can reliably predict clinical outcomes. These models need to be #scalable and #costeffective, compatible with #automation, and capable of delivering diverse readouts for complex phenotypic analysis. Our 3D InSight™ MASH model consists of primary human ✔️hepatocytes, ✔️Kupffer cells, ✔️endothelial cells, and ✔️stellate cells. These healthy liver spheroids are exposed to steatotic and pro-inflammatory media conditions, which over 🗓10 days result in the main hallmarks of human MASH (steatosis, inflammation, and fibrosis). At InSphero we take the next step in drug discovery for MASH by launching the MASH CALL Initiative – an exciting opportunity to push the boundaries of what's possible in drug discovery and bring new, effective treatments to the market faster 🚀   Join the MASH CALL by 🗓 September 6 and let's work together to revolutionize the future of MASH therapeutics! 💊 Learn more via the link in comments 👇 Francisco Verdeguer Radina Kostadinova, PhD Jesus Francisco Glaus Garzon Angelina Freitag Joel Zvick Philip Vonschallen Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Madhu Lal Nag, MBS PhD Jan Lichtenberg Rositsa Hadzhipetrova Tina Žel #DrugDiscovery #Innovation #Healthcare #MASHCALL #Pharma #3DModels #PhenotypicAnalysis

The article summarizes the existing research on the molecular mechanisms of cannabinoids regulation of the TME and finally highlights the human studies on cannabinoids' active interventional clinical trials. The conclusion outlines the need for future research involving clinical trials of cannabinoids to demonstrate their efficacy and activity as a treatment/prevention for various types of human malignancies. https://lnkd.in/g47w_QJY

Only put off until tomorrow what you are willing to die having left undone. ## Update on Molecular Partners' MP0533 and MP0621 Studies: Promising Safety and Efficacy in Ongoing Clinical Trials Quiver AI Summary: Molecular Partners AG has made significant advancements in their ongoing clinical trials for MP0533 and MP0621. The phase 1/2a dose escalation study of MP0533 has demonstrated an acceptable safety profile and initial indications of antileukemic activity in patients. This development brings hope to those seeking effective treatments for leukemia and other related conditions. Inspiring Investors to Take Action: Investors, don't miss out on the opportunity to contribute to the future of healthcare and potentially earn substantial returns. By investing in companies like Molecular Partners, you can support groundbreaking research and development in the field of oncology. Investing in Health Savings Accounts \(HSAs\) can be a wise financial move, allowing you to grow your funds tax-free while saving for future medical expenses. With the potential for significant returns and the chance to make a positive impact on people's lives, now is the time to act. Don't wait! Join the healthcare revolution and invest in your own future and the well-being of others. Take advantage of the power of HSAs and invest in companies like Molecular Partners to secure a healthier tomorrow for you, your family, and our society. #HSA #Investing #Healthcare #Health #Family #Wellness 💪💰🏥🌱💚✨

An international working group is proposing a new way to define Parkinson's disease based on biomarkers (specifically, the protein alpha-synuclein), a system which they believe can accelerate drug development. "We recognize that a biological definition for Parkinson's disease and dementia with Lewy bodies is a major shift," the authors wrote in the position paper. #healthcare #biotech #precisionmedicine https://lnkd.in/gCDF6m3t via GenomeWeb

Molecular Cytogenetics Market Future Scope, Outlook, Size, Share, Latest Trends, Growth Factors, Advance Technology And Forecast – 2028: North America held the predominant portion of the molecular cytogenetics market. The dominant share of the molecular cytogenetics market resides in North America, thanks to its advanced healthcare infrastructure and significant investments in healthcare. The global molecular cytogenetics market in … Continue reading → #HealthMedicine #PharmaceuticalsBiotech #UK #US #World